Laparoscopic Bariatric Surgery, Nausea and Vomiting
Conditions
Brief summary
Purpose: To explore and compare Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative nausea and vomiting and Early Outcome After Laparoscopic Bariatric Surgery To evaluate and examine TAPB can reduce the application of intraoperative and postoperative opioids and the duration of analgesia
Detailed description
Poor postoperative nausea and vomiting control is a leading factor that hinders the physical rehabilitation, and causes acute cognitive impairment and chronic pain syndrome. Recently, the multimodal analgesia strategies to minimise opioid-related side effects are highly desirable in open surgical procedures. The transversus abdominis plane block is a novel technique involving injection of local anaesthetic between the internal oblique and the transversus abdominis muscles of the abdominal wall. Although ropivacaine is most commonly used for this technique, the analgesic duration remains not dissatisfied. Herein, we will evaluate the efficacy of ultrasound-guided transversus abdominis plane (USG-TAP) block with ropivacaine in Laparoscopic Bariatric Surgery
Interventions
DRUGRopivacaine
Before the induction of anesthesia, ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Sponsors
Tianjin Medical University General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Subject is scheduled to undergo Laparoscopic Bariatric Surgery 2. Subject's American Society of Anesthesiologists physical status is I-III. 3. BMI\>35kg/m2 4. The subject's parent/legally authorized guardian has given written informed consent to participate
Exclusion criteria
1. Subject has a diagnosis of renal or liver failure. 2. Subject has a diagnosis of mental illness 3. Subject is allergy and contraindication to Ropivacaine. 4. Subject has a history of chronic pain, a history of alcohol or opioid abuse, pre-existing therapy with opioids, intake of any analgesic drug within 48 hours before surgery. 5. Subject has any contraindication for the use of patient-controlled analgesia (PCA). 6. Subject is pregnant or breast-feeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative nausea and vomiting | 72 hours after surgery | Postoperative nausea and vomiting |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative Sufentanyl Consumption | 24 hours after surgery | Each patient was administered analgesics using a PCA pump containing sufentanil (100μg) in normal saline at a total volume of 100 ml after leaving PACU. This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Sufentanyl cumulative consumption is recorded 24 hours postoperatively |
| Time of First Postoperative Analgesic Requirement | 1 hour after surgery | First postoperative pain (NRS≥4) is initially controlled by titration of sufentanyl |
| Occurrence of Side Effects | 24 hours after surgery | Occurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus |
| Total Dose of First Postoperative Analgesic Requirement | 1 hour after surgery | First postoperative pain (NRS≥4) is initially controlled by titration of sufentanyl. |
Countries
China
Contacts
Primary ContactZhen Jia, MD
Outcome results
None listed